# GigaMune

Source: https://onco.cc/companies/gigamune/  
OnCo record `gigamune` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

GigaMune is a San Francisco company building viral carriers that turn a patient's own T cells into cancer-fighting cells inside the body, designed so that the treatment can be given more than once. NCI funds its work on melanoma.

## Summary

GigaMune, Inc., of San Francisco, develops in vivo CAR-T therapies and says it holds hundreds of unrelated pseudotypes, viral vectors with different envelope proteins, so that repeat doses are not blocked by immunity to the first vector. The website cites its patent US 12,371,689 B2 and shows preclinical mouse data. In fiscal year 2026 NCI awarded it USD 1,000,000 under SBIR grant 4R44CA310160-02 for a lentivector to deliver T cell receptors in vivo as a cell therapy for stage IV melanoma.

## Fields

- Kind: Company
- Last checked: 2026-11-04
- Also known as: GigaMune, Inc.; GIGAMUNE, INC.
- HQ: San Francisco, CA
- Type: cell-therapy
- Website: https://gigamune.com/

## Notes

- Founding year and named programmes not stated on the website. Read on gigamune.com and NIH RePORTER on 4 November 2026.

## Sources

- Official website: https://gigamune.com/
- NIH RePORTER: award 4R44CA310160-02: https://reporter.nih.gov/project-details/11457449

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/)
- fronts: [Cell Therapy](https://onco.cc/fronts/cell-therapy/), [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [In vivo CAR-T](https://onco.cc/technologies/in-vivo-car-t/)

---
JSON: https://onco.cc/api/v1/entities/gigamune.json